Downmodulation of c-myc expression by interferon gamma and tumour necrosis factor alpha precedes growth arrest in human melanoma cells

Eur J Cancer. 1992;28A(10):1622-7. doi: 10.1016/0959-8049(92)90055-7.

Abstract

After in vitro incubation of melanoma tumour cells Cmel453A with either recombinant interferon gamma (rIFN-gamma) or tumour necrosis factor alpha (rTNF-alpha) a dose-dependent inhibition of cell growth occurred; when both cytokines were added, a synergistic action was observed. Inhibition of DNA synthesis, as measured by [3H] thymidine incorporation, occurred after 6 h of incubation with rIFN-gamma or rTNF-alpha, and this action was potentiated when the two cytokines were applied simultaneously. Within 1 h, the level of c-myc mRNA in tumour cells had already decreased by, respectively, 60% (S.D. 7) and 25% (S.D. 7); the combined addition of the cytokines resulted in a greater reduction of c-myc mRNA than by each cytokine alone. Downregulation of c-myc expression is an early event, occurring hours before the actual inhibition of outgrowth. Thus, in melanoma cells like Cmel with a high constitutive expression of the c-myc oncogene, the antiproliferative action of rIFN-gamma and rTNF-alpha may be mediated by an inhibition of the expression of c-myc.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antigens, Neoplasm / analysis
  • Cell Division / drug effects
  • Cycloheximide / pharmacology
  • Gene Expression Regulation, Neoplastic / drug effects*
  • Genes, myc / drug effects*
  • Histocompatibility Antigens Class I / analysis
  • Humans
  • Interferon-gamma / pharmacology*
  • Melanoma / genetics*
  • Melanoma / immunology
  • Melanoma / pathology
  • Recombinant Proteins / pharmacology
  • Time Factors
  • Tumor Cells, Cultured / drug effects
  • Tumor Necrosis Factor-alpha / pharmacology*

Substances

  • Antigens, Neoplasm
  • Histocompatibility Antigens Class I
  • Recombinant Proteins
  • Tumor Necrosis Factor-alpha
  • Interferon-gamma
  • Cycloheximide